MeMed has developed an immune-based protein signature, which distinguishes between bacterial and viral infections.

Founded in 2009, MeMed has developed a number of tools for innovative diagnostic testing and platforms.

April 20, 2017 | MeMed, an Israeli start-up developing a reliable test to distinguish bacterial from viral infections, has secured a $9.2 million contract by the Defense Threat Reduction Agency (DTRA), a branch of the US Department of Defense (DoD) to improve clinical applications of its technology. The contract will fund the completion of MeMed’s pioneering point of […]

Israeli startups are changing healthcare as we know it, with a host of innovative solutions.